RSC Advances



View Article Online

View Journal | View Issue

PAPER

Check for updates

Cite this: RSC Adv., 2017, 7, 44961

Received 21st August 2017 Accepted 12th September 2017

DOI: 10.1039/c7ra09229f

rsc.li/rsc-advances

1. Introduction

MicroRNAs (miRNAs) are small non-coding RNA molecules $(\sim 22 \text{ nt})$ that can regulate gene expression at the posttranscriptional level.1 Accumulating evidence indicates that miRNA mutations and dysregulations are closely related to various human diseases,² including cardiovascular diseases,³ schizophrenia,4 and cancer.5,6 Thus, identification of diseaserelated miRNAs will be helpful in the diagnosis, treatment, and prevention of diseases. Biological experiment methods such as microarray profiling and qRT-PCR can effectively identify miRNA-disease associations. For instance, Manavalan et al.7 confirmed miRs-10a, 21, 22, 29a, 93, 125b, 181, 200a, 200b, 200c, 205, and 222, which are associated with human breast cancer cells by microarray profiling. Some associations between miRNAs and diseases have been reported over the last few years. A number of researchers have constructed a miRNAdisease association database by collecting data from experiments that support human miRNAs and disease associations from published studies. These databases include HMDD,8 miR2Disease,9 dbDEMC,10,11 and PhenomiR,12 which provide

Network-based collaborative filtering recommendation model for inferring novel disease-related miRNAs

Changlong Gu, 📴 ^a Bo Liao, *^a Xiaoying Li,^a Lijun Cai,^a Haowen Chen,^a Keqin Li^b and Jialiang Yang^c

MicroRNAs (miRNAs) play important roles in the pathogenesis and development of many complex diseases. The experimental confirmation of disease-related miRNAs is costly and time-consuming. An efficient and accurate computational model for identifying potential miRNA-disease associations is a useful supplement for experimental approaches. In this study, we develop a new method for measuring miRNA and disease similarities, which are key issues in identifying miRNA-disease associations, based on normalized mutual information. Subsequently, a network-based collaborative filtering recommendation model, network-based collaborative filtering (NetCF), is proposed for predicting potential miRNA-disease associations. Leave-one-out cross validation is implemented to evaluate the predicted performance of NetCF. NetCF obtains a reliable AUC value of 0.8960, which is superior to other competitive methods. Implementing NetCF to predict lung cancer and prostate cancer-related miRNAs, 94% of the top 50 predicted miRNAs of each cancer have been confirmed by other databases.

a strong data basis for studying miRNAs. However, only a small amount of miRNA-disease associations have been reported in these databases. Due to the high cost and long time required for the identification of disease-related miRNAs through biological experimental methods, effective computational approaches for predicting disease-related miRNAs received great attention.

Several computational models have been developed to infer potential miRNA-disease associations. The aforementioned methods can be divided into two categories: network-based methods and machine-learning-based methods.¹³

The key problem of network-based methods is predicting that miRNA-disease associations are similar to the calculation among miRNAs and diseases over the networks. Some approaches have been reported to measure miRNA and disease similarities;14-16 Zou et al.17 reviewed the main similarity computation methods. Based on the common assumption that miRNAs are normally associated with phenotypically similar diseases and vice versa, Jiang et al.18 constructed a functionally related miRNA network and a human phenome-miRNAome network to prioritize potential disease-related miRNAs. However, the main limitation of this method is the high number of false positives that are produced in the miRNA target prediction step. To improve predicted performance, Jiang et al.19 subsequently proposed a Naive Bayes model to infer disease-related miRNAs by integrating multiple types of data resources. Some researchers have successfully applied the random walk algorithm to predict miRNA-disease associations.²⁰⁻²² Based on global network similarity measures, Chen

^aCollege of Information Science and Engineering, Hunan University, Changsha, Hunan 410082, China. E-mail: dragonbw@163.com

^bDepartment of Computer Science, State University of New York, New Paltz, New York 12561, USA

^cDepartment of Genetics and Gnomic Science, Icahn School of Medicine at Mount Sinai, New York 10029, USA

RSC Advances

et al.21 constructed a miRNA-miRNA functional similarity network and implemented Random Walk with Restart (RWR) from known disease-related miRNA seed nodes to prioritize potential disease-related miRNAs. By integrating disease-gene associations, miRNA-mRNA interactions, and protein-protein interactions, Shi et al.22 developed an improved method based on RWR to predict disease-related miRNAs and achieved a satisfactory performance with cross validation. Liu et al.²⁰ recently constructed a heterogeneous network by connecting disease and miRNA similarity subnetworks using known miRNA-disease associations and extended RWR method to infer potential miRNA-disease associations in the heterogeneous network. Although the RWR method presented good performance in predicting miRNA-disease associations, it cannot be implemented to diseases without any known associated miRNA. A similarity-based method called networkconsistency-based inference (NetCBI) has been proposed by Chen et al.23 to predict miRNA-disease associations. NetCBI can predict disease-related miRNAs when diseases have no known associated miRNA. However, the cross validation exhibited poor performance. Xuan et al.24 presented a novel method (HDMP) after considering the local information of network, based on weighted k where most similar neighbors predict diseaserelated miRNAs. Cross validation and case studies of HDMP indicate good predicted performance, but it does not work for diseases without known related miRNAs. Furthermore, based solely on gene expression profiles, Zhao et al.25 presented a computational framework to identify the cancer-related miRNAs, and constructed a cancer-miRNA-pathway network, which can help explain how miRNAs are involved in cancer. Recently, Qin et al.26 proposed a method to predict diseaseassociated miRNAs based on protein domains. The results on real datasets demonstrate the effectiveness of the approach.

Some researchers proposed machine-learning-based methods to predict potential miRNA-disease associations. To distinguish positive miRNA-disease from large-scale negative miRNA-disease associations, Jiang et al.27 extracted a set of features from each positive and negative microRNAdisease association and trained a Support Vector Machine (SVM) classifier to predict novel miRNA-disease associations. Based on miRNA-disease heterogeneous network, Zeng et al.28 used a path-based measure named HeteSim,29 to calculate relevance between objects in the heterogeneous network and combined HeteSim scores with a machine learning method to predict novel miRNA-disease associations. The challenge of using machine-learning-based methods for predicting novel miRNA-disease associations is the difficulty in obtaining negative samples (a miRNA is not associated with a disease). Given that limited trials do not provide enough evidence to prove that miRNA is not associated with a disease, Chen et al.³⁰ proposed the Regularized Least Squares for miRNAdisease Associations (RLSMDA) to prioritize potential miRNA-disease associations without utilizing negative samples. RLSMDA is a semi-supervised classification algorithm that can predict associations for disease without any associated miRNA.

By analyzing the aforementioned methods, the existing computation methods for predicting miRNA-disease associations are restricted by several limitations. First, some methods18 calculated miRNA similarities based on miRNA-mRNA database, and would produce higher false positives in the miRNA target prediction step. Second, some approaches^{21,23,24,30} calculated miRNA similarity based on the known miRNA-disease associations and evaluated their predicted performance through leave-one-out cross validation (LOOCV). The predicted performance would be overestimated, given that the similarity calculation has included the removal of the miRNA-disease association when LOOCV is performed.13 Third, some methods^{21,24} cannot be implemented to disease without any known associated miRNA. Finally, some machine-learningbased methods^{27,28} require negative samples to train classifiers; however, obtaining the negative samples is difficult.

To solve these complications, a network-based collaborative filtering recommend algorithm (NetCF) is proposed to reveal the potential associations between miRNAs and diseases. NetCF integrates miRNA and disease similarities along with the known miRNA-disease associations to reveal potential miRNA-disease associations. NetCF exhibits a clear advantage over other methods, which involve various features, such as LOOCV, case studies, global prediction for all diseases, prediction of disease without any known related miRNA (isolated disease), and prediction of miRNA with no associated disease (novel miRNA).

The main contributions of the paper are summarized as follows.

(1) miRNA similarities are calculated by experimentally verifying miRNA-mRNA interactions to eliminate false positives of the miRNA-target.

(2) miRNA and disease similarities are not dependent on the known miRNA-disease associations, so that LOOCV will not be too high to estimate its predicted performance.

(3) NetCF integrates miRNA- and disease-similarity-based recommendations to predict potential miRNA-disease associations. Therefore, when a disease is not related with any miRNA, the association can be predicted by miRNA-similarity-based recommendation. For the same reason, NetCF can also be applied to predict novel miRNA.

(4) NetCF uses similarity information and known miRNAdisease associations to infer potential miRNA-disease associations without requiring negative sample information.

2. Materials and methods

The flowchart of NetCF and the calculation of the predictive score between miRNA i and disease j are shown in Fig. 1.

2.1. Human miRNA-disease associations

The experimentally verified human miRNA-disease associations are downloaded from last updated HMDD database.⁸ We perform the following operations on these associations. The disease names are mapped to the disease MeSH description (https://www.ncbi.nlm.nih.gov/mesh). Repeated associations and several diseases without any MeSH descriptors or tree




Fig. 1 The flowchart of NetCF. NetCF calculates the association score between miRNA *i* and disease *j* is divided into three steps: (1) miRNA similarities are calculated based on known miRNA–mRNA interactions. (2) The disease functional similarities are calculated based on the known disease–mRNA interactions, and the disease semantic similarities are calculated based on disease MeSH tree structures, and then they are integrated to obtain disease similarities. (3) Based on the similarity information between miRNA *i* and their neighbors and the association information between the neighbors and disease *j*, the miRNA-similarity-based recommendation score, between miRNA *i* and disease *j* is calculated. Using a similar method to calculate the disease-similarity-based recommendation score, and then they were integrated to obtain the final prediction score.

numbers are removed. Moreover, the experimentally verified disease-related genes from the DisGeNET database³¹ are used to calculate disease similarity; thus, the disease names from the DisGeNET database are also mapped to the MeSH description and the diseases not found in the DisGeNET database are removed. After this treatment, 5048 distinct high-quality experimentally verified miRNA-disease associations are obtained, including 475 miRNAs and 334 diseases. We use this dataset as the benchmark dataset and variables nm and nd to represent the number of miRNAs and diseases, respectively. The adjacency matrix of miRNA-disease associations is denoted by matrix AS, whereas the entity AS(i,j) in row i and column j is 1 if miRNA i is associated with disease j, and 0 otherwise.

2.2. miRNA similarity measurement

The miRNA and disease similarities calculated based on known miRNA-disease associations overestimate predicted performance when cross validation is implemented. Based on the assumption that miRNAs with similar functions tend to be associated with similar target genes (mRNA), we presented the measurement of the functional similarity of two miRNAs by considering their related target genes. To eliminate false positive miRNA-target, miRNA similarities are calculated using experimentally verified miRNA-mRNA interactions downloaded from the miRTarBase database,^{32,33} Release 6.1. Let set $T_{m}^{A} = \{T_{m}^{A}(1), T_{m}^{A}(2), ..., T_{m}^{A}(ma)\}$ and set $T_{m}^{B} =$

 ${T_m}^B(1), T_m}^B(2), ..., T_m}^B(mb)$ denote the target gene sets of miR-NAs *A* and *B*, where variables *ma* and *mb* are the number of target genes of miRNA *A* and *B*, respectively. The information entropy of T_m^A is defined in eqn (1):

$$\begin{cases} H(T_{m}^{A}) = -\sum_{i=1}^{ma} p(T_{m}^{A}(i)) \log_{2}(p(T_{m}^{A}(i))) \\ p(T_{m}^{A}(i)) = \frac{n(T_{m}^{A}(i))}{N} \end{cases}$$
(1)

where *N* is the number of miRNA–mRNA interactions; $n(T_m^A(i))$ is the number of the *i*th target gene of miRNA *A* in the miRNA–mRNA set; $p(T_m^A(i))$ is the frequency of the *i*th target gene of miRNA *A* in the miRNA-mRNA set; and $H(T_m^A)$ is the information entropy of T_m^A .

The normalized mutual information (NMI) of T_m^A and T_m^B is used to measure the functional similarity of miRNAs *A* and *B*:

$$MM(A, B) = \frac{2H(T_{m}^{A} \cap T_{m}^{B})}{H(T_{m}^{A}) + H(T_{m}^{B})}$$
(2)

where $H(T_m^{A})$, $H(T_m^{B})$ and $H(T_m^{A} \cap T_m^{B})$ represent the information entropy of T_m^{A} , T_m^{B} and the intersection set of T_m^{A} and T_m^{B} , respectively. The functional similarity between two miR-NAs is measured by eqn (2) according to their common target genes and the information entropy of their respective target gene sets; and it is standardized based on NMI. Matrix MM is the functional similarity matrix, and MM(i_i) in row i and column j represents the similarity between miRNAs i and j.

2.3. Disease similarity measurement

Disease similarity is composed of two parts: disease functional and disease semantic similarities.

Based on the common assumption that two diseases with similar functions are normally associated with similar target genes, we also used the NMI of two disease-target gene sets to measure their functional similarity. Experimentally-verified disease-mRNA interactions are employed in this study and downloaded from the DisGeNET database. We use sets $T_d^A = \{T_d^A(1), T_d^A(2), ..., T_d^A(da)\}$ and $T_d^B = \{T_d^B(1), T_d^B(2), ..., T_d^B(db)\}$ to denote the target gene set of diseases *A* and *B*, where *da* and *db* refer to the number of target genes of diseases *A* and *B*, respectively. Similar to the miRNA function similarity calculation, the NMI of T_d^A and T_d^B is used to measure the functional similarity between diseases *A* and *B* as follows:

$$DF(A,B) = \frac{2H(T_d^A \cap T_d^B)}{H(T_d^A) + H(T_d^B)}$$
(3)

where $H(T_d^A)$, $H(T_d^B)$ and $H(T_d^A \cap T_d^B)$ represent the information entropy of T_d^A , T_d^B and the intersection set of T_d^A and T_d^B , respectively. The functional similarity between two diseases is determined by their common target genes and the information entropy of their respective target gene sets.

An improved form of Wang's method¹⁴ for disease semantic similarity calculation is implemented in this paper. This method calculates disease semantic similarity based on the hierarchical structure of MeSH. A disease can be described as a directed acyclic graph (DAG), in which the nodes represent diseases, whereas the links represent the relationship between nodes. Let $DAG_d = (d, T_d, E_d)$ denote the DAG graph of disease *d*, where T_d is the node set (all ancestor nodes of disease *d* including disease *d* itself) and E_d is the connected edge set. Wang's method defines the semantic contribution of node $t \in T_d$ as follows:

$$D_{\rm d}(t) = \begin{cases} 1 & \text{if } t = d \\ \max \left\{ \Delta \times D_{\rm d} \left(t' \right) | t' \in \text{children of } t \right\} & \text{if } t \neq d \end{cases}$$
(4)

where Δ is the semantic contribution factor, and $\Delta = 0.5$ is used in their experiments. In this manner, the semantic contribution of the disease term is defined by only considering the hierarchical structure of the DAG graph. For example, the DAG graph of "Breast Neoplasms" and the semantic contribution (sc) values of each node are shown in Fig. 2.

The importance of the disease term itself is considered; for example, disease terms "liver neoplasms" and "neoplasms" are specifically described as "liver neoplasms", such that its semantic contribution value should be greater than the contribution value of "neoplasms." We use information content (IC) to measure the importance of the disease term itself:

$$IC(t) = -\log_2(p(t)) \tag{5}$$

where p(t) is the frequency of disease term t in the MeSH disease term set. Evidently, the larger the p(t) is, the more common description of disease t is and the smaller the semantic contribution value of disease t is. In this paper, the MeSH disease term set is downloaded from the MeSH homepage (2017 MeSH files), which contains 57 840 disease tree numbers with their corresponding disease terms. The semantic contribution value of disease t is obtained by integrating $D_d(t)$ and IC(t) as $C_d(t) = D_d(t) \times IC(t)$. The semantic similarity of diseases A and B can be calculated by their shared ancestors as follows:

$$DS(A, B) = \frac{\sum_{t \in (T_A \cap T_B)} (C_A(t) + C_B(t))}{\sum_{t \in T_A} (C_A(t)) + \sum_{t \in T_B} (C_B(t))}$$
(6)

Finally, the similarity between diseases *A* and *B* is calculated by integrating disease functional and disease semantic similarities as follows:




Fig. 2 The DAG graph of "Breast Neoplasms" and the semantic contribution values of each node.

$$DD(A,B) = \alpha DF(A,B) + (1 - \alpha)DS(A,B)$$
(7)

where $\alpha \in [0,1]$ is the weight coefficient used to indicate the importance of disease functional and semantic similarities. In our experiments, we regard the two parts are equally important; thus, α set to 0.5. Matrix DD is the similarity matrix and DD(*i*,*j*) in row *i* and column *j* represents the similarity between diseases *i* and *j*.

2.4. NetCF

Collaborative filtering (CF) algorithm is one of the most important techniques used by recommender systems,³⁴ and it has enjoyed tremendous success in e-business, marketing, and other personalized recommendation services. CF algorithm generates recommendations or predictions based on observed preferences.³⁵ In this study, by integrating the miRNA similarity, disease similarity, and known miRNAdisease association networks, a NetCF recommendation model is proposed to predict potential miRNA-disease associations. NetCF is implemented in three steps as follows: (1) miRNA-similarity-based recommendation score calculation; (2) disease-similarity-based recommendation score calculation; (3) and the calculation of final predictor score of potential miRNA-disease associations by integrating the results of steps (1) and (2).

The detailed implementation procedure of NetCF for calculating the predictor score between miRNA i and disease j is as follows.

First, based on the similarity information between miRNA i and their neighbors and the association information between the neighbors and disease j, the miRNA-similarity-based recommendation score between miRNA i and disease j is calculated. Evidently, if the similarity between a neighbor and miRNA i is extremely small, then the contribution of the neighbor can be ignored. The miRNA-similarity-based recommendation score according to the n most similar neighbors of miRNA i is calculated as follows:

$$\mathbf{RS}_{\mathrm{m}}(i,j) = \frac{1}{n} \sum_{k=1}^{n} \mathbf{MM}(i,k) \times \mathbf{AS}(k,j)$$
(8)

where MM(*i*,*k*) is the similarity value between the k^{th} most similar neighbor of miRNA *i* and miRNA *k*, and AS(*k*,*j*) is the association information between the k^{th} most similar neighbor of miRNA *i* and disease *j*. In our experiments, the value of parameter *n* is 10% of the miRNA number (nm/10). Matrix RS_m is the miRNA-similarity-based recommendation score matrix, and RS_m(*i*,*j*) in row *i* and column *j* represents the miRNAsimilarity-based recommendation score between miRNA *i* and disease *j*.

Second, the disease-similarity-based recommendation score between miRNA i and disease j is calculated based on the similarity information between disease j and their neighbors and the association information between the neighbors and miRNA i. For the same reason, the disease-similarity-based recommendation score is calculated by the m most similar neighbors of disease j as follows:

$$\mathbf{RS}_{d}(i,j) = \frac{1}{m} \sum_{k=1}^{m} \mathbf{AS}(i,k) \times \mathbf{DD}(k,j)$$
(9)

where $DD(k_j)$ is the similarity value between the k^{th} most similar neighbor of disease k and disease j, and AS(i,k) is the association information between the k^{th} most similar neighbor of disease jand miRNA i. In our experiments, the value of parameter m is 10% of the disease number (nd/10). Matrix RS_d is the diseasesimilarity-based recommendation score matrix, and RS_d(i_j) in row i and column j represents the disease-similarity-based recommendation score between miRNA i and disease j.

Finally, miRNA- and disease-similarity-based recommendation scores are integrated as the final recommendation score of miRNA i and disease j as follows:

$$RS(i,j) = \beta RS_{m}(i,j) + (1-\beta)RS_{d}(i,j)$$
(10)

where $RS_m(i,j)$ and $RS_d(i,j)$ are the miRNA-based and the disease-similarity-based recommendation scores between




Fig. 3 Performance comparisons of NetCF, Liu's method, NetCBI, RLSMDA, and KATZMDA in terms of ROC curves and AUCs based on LOOCV.




Fig. 4 The parameters effects on NetCF.

Table 1 The top 50 potential lung cancer-related miRNAs predicted by NetCF, 47 of them were confirmed by dbDEMC and PhenomiR databases

Rank	miRNA	Evidences
1	hsa-mir-16	dbDEMC,
		PhenomiR
2	hsa-mir-195	dbDEMC,
		PhenomiR
3	hsa-mir-429	dbDEMC
4	hsa-mir-15a	dbDEMC,
		PhenomiR
5	hsa-mir-451a	dbDEMC
6	hsa-mir-141	dbDEMC,
		PhenomiR
7	hsa-mir-106b	dbDEMC,
		PhenomiR
8	hsa-mir-449a	PhenomiR
9	hsa-mir-193b	dbDEMC,
		PhenomiR
10	hsa-mir-302d	PhenomiR
11	hsa-mir-383	PhenomiR
12	hsa-mir-20b	dbDEMC,
		PhenomiR
13	hsa-mir-194	dbDEMC,
		PhenomiR
14	hsa-mir-130a	dbDEMC,
		PhenomiR
15	hsa-mir-151a	dbDEMC
16	hsa-mir-99a	dbDEMC,
		PhenomiR
17	hsa-mir-296	dbDEMC,
		PhenomiR
18	hsa-mir-320a	dbDEMC,
		PhenomiR
19	hsa-mir-215	PhenomiR
20	hsa-mir-378a	dbDEMC
21	hsa-mir-15b	dbDEMC,
		PhenomiR
22	hsa-mir-153	dbDEMC,
		PhenomiR
23	hsa-mir-328	dbDEMC,
		PhenomiR
24	hsa-mir-149	dbDEMC,
		PhenomiR
25	hsa-mir-302c	PhenomiR
26	hsa-mir-130b	dbDEMC,
		PhenomiR
27	hsa-mir-122	PhenomiR
28	hsa-mir-302a	PhenomiR
29	hsa-mir-449b	PhenomiR
30	hsa-mir-10a	dbDEMC,
		PhenomiR
31	hsa-mir-152	dbDEMC,
		PhenomiR
32	hsa-mir-147	dbDEMC
33	hsa-mir-302b	PhenomiR
34	hsa-mir-204	dbDEMC,
		PhenomiR
35	hsa-mir-181d	dbDEMC,
26		PhenomiR
36	hsa-mir-139	dbDEMC,
		PhenomiR
37	hsa-mir-372	PhenomiR
38	hsa-mir-196b	dbDEMC,
		PhenomiR

Table 1 (Contd.)

Rank	miRNA	Evidences
39	hsa-mir-423	dbDEMC,
		PhenomiR
0	hsa-mir-148b	dbDEMC,
		PhenomiR
L	hsa-mir-520g	Unconfirmed
	hsa-mir-615	dbDEMC
	hsa-mir-151b	dbDEMC
	hsa-mir-373	PhenomiR
	hsa-mir-452	dbDEMC,
		PhenomiR
5	hsa-mir-367	PhenomiR
,	hsa-mir-630	Unconfirmed
	hsa-mir-324	dbDEMC,
		PhenomiR
	hsa-mir-519c	Unconfirmed

miRNA *i* and disease *j*, respectively. Parameter $\beta \in [0,1]$ is the integrated parameter used to indicate the importance of $RS_m(i,j)$ and $RS_d(i,j)$. In our experiments, parameter β is set to $\beta = nm/(nm + nd)$ balance the numbers of miRNAs and diseases. Matrix RS is the final recommendation score matrix, and RS(i,j) in row *i* and column *j* represents the final recommendation score between miRNA *i* and disease *j*.

hsa-mir-625

3. Results

50

3.1. Performance evaluation

The predicted performance of NetCF is compared with the other four state-of-the-art computational models, *i.e.*, Liu's method,²⁰ NetCBI,²³ RLSMDA,³⁰ and KATZ.³⁶

Using our proposed similarity computation method to measure the similarity of miRNA and disease, LOOCV is implemented on the benchmark dataset; and receiver operating characteristic (ROC) curve and the area under ROC curve (AUC) are adopted to evaluate the predicted performance of NetCF and comparison methods. The four parameters of NetCF are set to $\alpha = 0.5$, $\beta = \text{nm/(nm + nd)}$, n = 47, and m = 33. Optimal parameters are selected for Liu's method, NetCBI, RLSMDA, and KATZ as described in their literatures. The ROC curves of NetCF and comparison methods are plotted in Fig. 3, and the AUC values are indicated in the legends.

The AUC value of NetCF is 0.8960, whereas those of Liu's method, NetCBI, RLSMDA, and KATZ are 0.7974, 0.8105, 0.8406, and 0.8315, respectively. All methods obtained a reliable AUC value when LOOCV is implemented on the benchmark dataset, which proves the rationality of our miRNA and disease similarity measure.

Evidently, NetCF shows better predicted performance compared with Liu's method, NetCBI, RLSMDA, and KATZ.

3.2. Parameters effects

The value of Δ is set to 0.5 according to the suggestion in author's.¹⁴ The parameter *n* represents the number of the most similar neighbors of the query miRNA, and 10% of the number

dbDEMC

Paper

Rank

1

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

2.2

23

24

25 26

27

28

29

30

31

32

33 34

35

36

37

38

miRNA

hsa-mir-18a

Т

Evidences

dbDEMC,

Rank	miRNA	Evidences
39	hsa-mir-10a	dbDEMC,
		PhenomiR
40	hsa-mir-302b	PhenomiR
41	hsa-mir-615	dbDEMC
42	hsa-mir-365a	dbDEMC
43	hsa-mir-92b	Unconfirmed
44	hsa-mir-139	dbDEMC,
		PhenomiR
45	hsa-mir-423	dbDEMC,
		PhenomiR
46	hsa-mir-212	dbDEMC,
		PhenomiR
47	hsa-mir-137	PhenomiR
48	hsa-mir-181c	dbDEMC,
		PhenomiR
49	hsa-mir-497	dbDEMC,
		PhenomiR
50	hsa-mir-302c	PhenomiR

of miRNAs is empirically set. The parameter *m* is set in the same way. In this section, we mainly discuss the influence of the weight coefficient α and the integrated parameter β on the predictive performance of NetCF. To evaluate the effects of the integrated parameter β , the other parameters are fixed ($\alpha = 0.5$, $\Delta = 0.5, n = 47$, and m = 33), and the value of parameter β changes from 0.1 to 0.9. Then, according to the optimal β value, the effects of parameter α on NetCF are tested in the same way. The results are shown in Fig. 4. When the parameter α varies from 0.1 to 0.9, the range of AUCs is 0.8927 to 0.8970; and when the parameter β varies from 0.1 to 0.9, the range of AUCs is 0.8732 to 0.8970. Therefore, NetCF is not sensitive to these two parameters. And for the integrated parameter β , we do not want to be too focused on miRNA- or disease-similaritybased recommendation score. In the experiment we set $\beta =$ nm/(nm + nd), and the other parameters are set to $\alpha = 0.5$, $\Delta =$ 0.5, n = 47, and m = 33.

3.3. Case study

A large number of researchers have indicated that miRNA plays an important role in the development of various forms of cancer from different perspectives. To further evaluate the predicted performance of NetCF for predicting potential disease-related miRNAs, lung and prostate cancers are chosen as case studies. All known associations are used as training set, and recommendation scores are calculated using NetCF. The unknown associations of each disease are ranked according to their recommendation scores, and the top 50 are selected for further validation. The predicted results are verified based on the recently updated dbDEMC10 and PhenomiR12 databases. To explore aberrantly expressed miRNAs in different cancers, the dbDEMC database is used as different experimental designs and data sources. To obtain reliable results, we only chose the results of the experimental conditions "cancer vs. normal" and the data from TCGA (The Cancer Genome Atlas, https://

nsa-mir-18a	uddemc,
	PhenomiR
hsa-mir-155	PhenomiR
hsa-mir-429	Unconfirmed
hsa-mir-9	dbDEMC,
	PhenomiR
hsa-mir-19b	dbDEMC,
iibu iiii 196	PhenomiR
hsa-mir-19a	dbDEMC,
115a-1111-19a	PhenomiR
h a - m in 101 -	
hsa-mir-181a	dbDEMC,
	PhenomiR
hsa-mir-196a	dbDEMC,
	PhenomiR
hsa-mir-29c	dbDEMC,
	PhenomiR
hsa-mir-10b	PhenomiR
hsa-mir-138	PhenomiR
hsa-mir-24	dbDEMC,
	PhenomiR
hsa-mir-7	dbDEMC,
iibu iiiii /	PhenomiR
hsa-mir-210	dbDEMC,
115a-1111-210	PhenomiR
1	
hsa-mir-150	PhenomiR
hsa-mir-451a	dbDEMC
hsa-let-7e	dbDEMC,
	PhenomiR
hsa-mir-30a	dbDEMC,
	PhenomiR
hsa-mir-125a	dbDEMC,
	PhenomiR
hsa-mir-149	dbDEMC,
	PhenomiR
hsa-mir-103a	dbDEMC
hsa-let-7g	dbDEMC,
8	PhenomiR
hsa-mir-192	dbDEMC
hsa-mir-186	dbDEMC,
1158-1111-180	,
1	PhenomiR
hsa-mir-140	dbDEMC
hsa-mir-20b	dbDEMC
hsa-mir-302d	PhenomiR
hsa-mir-128	dbDEMC,
	PhenomiR
hsa-mir-328	dbDEMC,
	PhenomiR
hsa-mir-215	dbDEMC,
	PhenomiR
hsa-mir-383	dbDEMC,
	PhenomiR
hsa-mir-26b	dbDEMC,
1154 1111 200	PhenomiR
hee mir 202e	PhenomiR
hsa-mir-302a	
hsa-let-7f	dbDEMC,
	PhenomiR
hsa-mir-181d	dbDEMC
hsa-mir-142	PhenomiR
hsa-mir-449b	Unconfirmed
hsa-mir-197	dbDEMC,
	PhenomiR

Table 3The top 50 potential lung cancer-related miRNAs predictedby NetCF with removed all known lung cancer-miRNA associations, allof them were confirmed based on the dbDEMC and PhenomiRdatabases

Table 3	(Contd.)

Paper

14Isa min 1930Hommik Phenomikstudies, t Phenomik15hsa-mir-708dbDEMCdifferentia16hsa-mir-378adbDEMCbiological17hsa-mir-302cPhenomikprostate of18hsa-mir-152dbDEMC,confirmati19hsa-mir-625dbDEMC,listed in T20hsa-mir-204dbDEMC,The hig21hsa-mir-15bdbDEMC,women.3722hsa-mir-149dbDEMC,field by bi23hsa-mir-204dbDEMC,field by bi24hsa-mir-20bdbDEMC,miRNAs, 425hsa-mir-129dbDEMC,nomik da26hsa-mir-139dbDEMC,are not con27hsa-mir-139dbDEMC,are not con28hsa-mir-194dbDEMC,set not con29hsa-mir-10adbDEMC,field pield bi29hsa-mir-320adbDEMC,field pield bi30hsa-mir-320adbDEMC,field pield bi31hsa-mir-302dPhenomikBiologi33hsa-mir-196bdbDEMC,miRNAs.	Rank	miRNA	Evidences	38
PhenomikTheomik2hsa-mir-15aPhenomik423hsa-mir-15aPhenomik423hsa-mir-15adbDEMC,444hsa-mir-15dbDEMC,445hsa-mir-151adbDEMC,445hsa-mir-10adbDEMC,456hsa-mir-10aPhenomik467hsa-mir-10bPhenomik467hsa-mir-10bdbDEMC,479hsa-mir-296dbDEMC,4911hsa-mir-222Phenomik5011hsa-mir-122Phenomik5012hsa-mir-41adbDEMC,4913hsa-mir-193dbDEMC,monopoly14hsa-mir-103dbDEMC,cancergen15hsa-mir-378adbDEMCdifferentia16hsa-mir-378adbDEMC,prostate of17hsa-mir-322Phenomikconfirmati19hsa-mir-152dbDEMC,robema, women, wom				39
2 hsa-mir-15a dbDEMC, PhenomiR 42 3 hsa-mir-155 dbDEMC, PhenomiR 43 4 hsa-mir-151a dbDEMC, PhenomiR 43 4 hsa-mir-151a dbDEMC, PhenomiR 46 5 hsa-mir-130a dbDEMC, PhenomiR 46 7 hsa-mir-302b PhenomiR 46 7 hsa-mir-16b dbDEMC, PhenomiR 49 9 hsa-mir-122 PhenomiR 50 10 hsa-mir-26 dbDEMC, PhenomiR 49 11 hsa-mir-193 dbDEMC, PhenomiR 49 12 hsa-mir-302a PhenomiR 50 13 hsa-mir-193b dbDEMC, PhenomiR 50 14 hsa-mir-378a dbDEMC, PhenomiR 50 15 hsa-mir-378a dbDEMC, PhenomiR confirmati Confirmati 16 hsa-mir-32c dbDEMC, PhenomiR confirmati Confirmati 15 hsa-mir-32a PhenomiR confirmati Confirmati 20 hsa-mir-32a dbDEMC, PhenomiR dbDEMC, Woren. ³⁷ 21 hsa-mir-32a	1	hsa-mir-16		40
PhenomiR 42 3 hsa-mir-195 dbDEMC, 4 hsa-mir-131a dbDEMC, 44 5 hsa-mir-131a dbDEMC, 44 5 hsa-mir-130a dbDEMC, 45 6 hsa-mir-130a dbDEMC, 47 7 hsa-mir-302b PhenomiR 46 7 hsa-mir-106b dbDEMC, 47 9 hsa-mir-129 dbDEMC, 48 10 hsa-mir-206 dbDEMC, 49 11 hsa-mir-106b dbDEMC, 49 12 hsa-mir-106 dbDEMC, 49 14 hsa-mir-108 dbDEMC, 41 15 hsa-mir-108 dbDEMC, 41 14 hsa-mir-108 dbDEMC, 41 15 hsa-mir-378a dbDEMC, confirmati 16 hsa-mir-378a dbDEMC, toloiogical 17 hsa-mir-378a dbDEMC, confirmati 18 hsa-mir-108 dbDEMC, toloiogical 19 hsa-mir-378a dbDEMC, confirmati 21 hsa-mir-139 dbDEMC, dysregulat 22 hsa-mir-139 dbDEMC, dysregulat	2	has min 15a		
3 hsa-mir-195 dbDEMC, $PhenomiR 43$ 4 hsa-mir-141 dbDEMC, 44 PhenomiR 43 5 hsa-mir-151a dbDEMC 45 6 hsa-mir-130a dbDEMC 45 6 hsa-mir-302b PhenomiR 46 7 hsa-mir-302b PhenomiR 46 7 hsa-mir-29 dbDEMC 48 10 hsa-mir-29 dbDEMC, 49 PhenomiR 50 11 hsa-mir-122 PhenomiR 50 11 hsa-mir-122 PhenomiR 50 12 hsa-mir-151a dbDEMC 48 13 hsa-mir-193b dbDEMC 50 14 hsa-mir-193b dbDEMC 61 15 hsa-mir-302 PhenomiR 50 15 hsa-mir-302 PhenomiR 50 16 hsa-mir-302 PhenomiR 50 17 hsa-mir-193b dbDEMC 61 18 hsa-mir-193b dbDEMC 61 19 hsa-mir-152 PhenomiR 70 10 hsa-mir-302 PhenomiR 51 10 hsa-mir-302 PhenomiR 51 11 hsa-mir-193b dbDEMC 61 12 hsa-mir-302 PhenomiR 70 13 hsa-mir-302 PhenomiR 70 14 hsa-mir-302 PhenomiR 70 15 hsa-mir-308 dbDEMC 61 16 hsa-mir-302 PhenomiR 70 17 hsa-mir-302 PhenomiR 70 18 hsa-mir-152 dbDEMC 11 19 hsa-mir-204 dbDEMC, 70 19 hsa-mir-204 dbDEMC, 70 20 hsa-mir-204 dbDEMC, 70 21 hsa-mir-204 dbDEMC, 70 22 hsa-mir-328 dbDEMC, 70 23 hsa-mir-328 dbDEMC, 70 24 hsa-mir-302 PhenomiR 70 25 hsa-mir-328 dbDEMC, 70 26 hsa-mir-30 dbDEMC, 70 27 hsa-mir-328 dbDEMC, 70 29 hsa-mir-328 dbDEMC, 70 20 hsa-mir-328 dbDEMC, 70 21 hsa-mir-328 dbDEMC, 70 22 hsa-mir-328 dbDEMC, 70 23 hsa-mir-328 dbDEMC, 70 24 hsa-mir-328 dbDEMC, 70 25 hsa-mir-328 dbDEMC, 70 26 hsa-mir-329 dbDEMC, 70 27 hsa-mir-320 PhenomiR 70 28 hsa-mir-320 PhenomiR 70 29 hsa-mir-320 PhenomiR 70 20 hsa-mir-320 PhenomiR 70 21 hsa-mir-320 PhenomiR 70 23 hsa-mir-320 PhenomiR 70 24 hsa-mir-320 PhenomiR 70 25 hsa-mir-320 PhenomiR 70 26 hsa-mir-320 PhenomiR 70 27 hsa-mir-320 PhenomiR 70 28 hsa-mir-320 PhenomiR 70 29 hsa-mir-320 PhenomiR 81 30 hsa-mir-320 PhenomiR 81 31 hsa-mir-320 PhenomiR 70 32 hsa-mir-320 PhenomiR 70 33 hsa-mir-320 PhenomiR 70 34 hsa-mir-320 PhenomiR 70 35 hsa-mir-151 PhenomiR 70 36 hsa-mir-151 PhenomiR 70 37 hsa-mir-99 PhenomiR 70 36 hsa-mir-150 PhenomiR 70 37 hsa-mir-99 PhenomiR 70 36 hsa-mir-150 PhenomiR 70 37 hsa-mir-99 PhenomiR 70 36 hsa-mir-150 PhenomiR 70 37 hsa-mir-99 PhenomiR 70 36 hsa-mir	2	nsa-mir-15a	,	
4hsa-mir-141PhenomiR4344hsa-mir-151adbDEMC,445hsa-mir-130adbDEMC,456hsa-mir-302bPhenomiR467hsa-mir-302bPhenomiR78hsa-mir-106bdbDEMC,479hsa-mir-29dbDEMC,4810hsa-mir-296dbDEMC,4911hsa-mir-141dbDEMC,4912hsa-mir-141dbDEMC,4913hsa-mir-193bdbDEMC,4014hsa-mir-193bdbDEMC,cancergen15hsa-mir-378adbDEMC,cancergen16hsa-mir-378adbDEMC,confirmati17hsa-mir-302cPhenomiRconfirmati18hsa-mir-152dbDEMC,listed in T20hsa-mir-154dbDEMC,confirmati21hsa-mir-15bdbDEMC,menoniR22hsa-mir-129dbDEMC,dysregulat23hsa-mir-129dbDEMC,miRNAs, 424hsa-mir-302aPhenomiRmiRNAs, 425hsa-mir-139dbDEMC,confirmati26hsa-mir-139dbDEMC,confirmati27hsa-mir-302aPhenomiRmiRNAs, 428hsa-mir-139dbDEMC,cell-cycle I29hsa-mir-149dbDEMC,cell-cycle I20hsa-mir-139dbDEMC,cell-cycle I29hsa-mir-149dbDEMC,cell-cycle I20 <td>2</td> <td>hea-mir-105</td> <td></td> <td>42</td>	2	hea-mir-105		42
4hsa-mir-141dbDEMC, PhenomiR44 $PhenomiR$ PhenomiR455hsa-mir-130adbDEMC, PhenomiR467hsa-mir-302bPhenomiR478hsa-mir-106bdbDEMC, PhenomiR479hsa-mir-29dbDEMC4810hsa-mir-22PhenomiR5011hsa-mir-122PhenomiR5012hsa-mir-451adbDEMC4713hsa-mir-99adbDEMC, PhenomiR5014hsa-mir-193bdbDEMC, PhenomiRcancergen15hsa-mir-378adbDEMCbiological17hsa-mir-378adbDEMC, PhenomiRconfirmati19hsa-mir-625dbDEMC, PhenomiRconfirmati20hsa-mir-15bdbDEMC, PhenomiRconfirmati21hsa-mir-149dbDEMC, PhenomiRconfirmati22hsa-mir-13bdbDEMC, PhenomiRconfirmati23hsa-mir-139dbDEMC, PhenomiRmiRNAs, a24hsa-mir-139dbDEMC, PhenomiRmiRNAs, a25hsa-mir-139dbDEMC, PhenomiRare not con PhenomiR26hsa-mir-149dbDEMC, PhenomiRcalcerycel27hsa-mir-149dbDEMC, PhenomiRcalcerycel28hsa-mir-149dbDEMC, PhenomiRcalcerycel29hsa-mir-149dbDEMC, PhenomiRcalcerycel20hsa-mir-149dbDEMC, PhenomiRcalcerycel	5	115a-1111-195	,	42
PhenomikPhenomik5hsa-mir-151adbDEMC456hsa-mir-130adbDEMC457hsa-mir-302bPhenomik467hsa-mir-302bPhenomik479hsa-mir-106bdbDEMC4810hsa-mir-296dbDEMC4810hsa-mir-229Phenomik5011hsa-mir-1451adbDEMC4912hsa-mir-451adbDEMC4113hsa-mir-193bdbDEMC4114hsa-mir-193bdbDEMCdifferentia15hsa-mir-193bdbDEMCdifferentia16hsa-mir-378adbDEMCdifferentia17hsa-mir-302Phenomikconfirmat18hsa-mir-324dbDEMClisted in T20hsa-mir-204dbDEMCwomen. ³⁷ 21hsa-mir-15bdbDEMC,women. ³⁷ 22hsa-mir-129Phenomikwomen. ³⁷ 24hsa-mir-129dbDEMC,miRNAs a25hsa-mir-139dbDEMC,are not con26hsa-mir-139dbDEMC,are not con27hsa-mir-30aPhenomikparticular28hsa-mir-30aPhenomikmiRNAs a29hsa-mir-30aPhenomikmiRNAs a20hsa-mir-149Phenomikare not con21hsa-mir-139dbDEMC,nomik da22hsa-mir-139dbDEMC,are not con24hsa-mir-149Phenomi	4	hsa-mir-141		
6hsa-mir-130adbDEMC, PhenomiR467hsa-mir-302bPhenomiR468hsa-mir-106bdbDEMC, PhenomiR479hsa-mir-429dbDEMC, PhenomiR4910hsa-mir-122PhenomiR5011hsa-mir-124PhenomiR5012hsa-mir-131adbDEMC, PhenomiR4914hsa-mir-193bdbDEMC, PhenomiRcancergen PhenomiR15hsa-mir-193bdbDEMC, PhenomiRcancergen PhenomiR16hsa-mir-378adbDEMCliological17hsa-mir-302cPhenomiR PhenomiRconfirmati PhenomiR18hsa-mir-625dbDEMClisted in T20hsa-mir-625dbDEMC, PhenomiRconfirmati PhenomiR21hsa-mir-15bdbDEMC, PhenomiRdysregulat PhenomiR22hsa-mir-204dbDEMC, PhenomiRdysregulat PhenomiR23hsa-mir-328dbDEMC, PhenomiRmiRNAs a PhenomiR24hsa-mir-149dbDEMC, PhenomiRmiRNAs a PhenomiR25hsa-mir-139dbDEMC, PhenomiRare not con PhenomiR26hsa-mir-302aPhenomiR PhenomiRmart col PhenomiR27hsa-mir-302aPhenomiR PhenomiRassociation PhenomiR28hsa-mir-149dbDEMC, PhenomiRcell-cycle I PhenomiR29hsa-mir-139dbDEMC, PhenomiRcell-cycle I PhenomiR29hsa-mir-302aPhen			,	11
6hsa-mir-130a PhenomiRdbDEMC, PhenomiR467hsa-mir-302bPhenomiR47 PhenomiR8hsa-mir-106bdbDEMC, PhenomiR47 PhenomiR9hsa-mir-429dbDEMC, PhenomiR49 PhenomiR10hsa-mir-120PhenomiR11hsa-mir-121PhenomiR12hsa-mir-451adbDEMC, PhenomiR13hsa-mir-90adbDEMC, PhenomiR14hsa-mir-193bdbDEMC, PhenomiR15hsa-mir-708dbDEMC16hsa-mir-378adbDEMC17hsa-mir-302cPhenomiR PhenomiR18hsa-mir-625dbDEMC19hsa-mir-625dbDEMC, PhenomiRconfirmat confirmat20hsa-mir-149dbDEMC, PhenomiRdysregulat PhenomiR21hsa-mir-32adbDEMC, PhenomiRdysregulat PhenomiR22hsa-mir-32adbDEMC, PhenomiRmiRNAs a OphenomiR23hsa-mir-32adbDEMC, PhenomiRmiRNAs, 4 PhenomiR24hsa-mir-149dbDEMC, PhenomiRmiRNAs a PhenomiR25hsa-mir-139dbDEMC, PhenomiRare not con PhenomiR26hsa-mir-149dbDEMC, PhenomiRcell-cycle I PhenomiR27hsa-mir-149dbDEMC, PhenomiRcell-cycle I PhenomiR28hsa-mir-149dbDEMC, PhenomiRcell-cycle I PhenomiR29hsa-mir-149dbDEMC, PhenomiRcell-cycle I PhenomiR <t< td=""><td>5</td><td>hsa-mir-151a</td><td>dbDEMC</td><td>45</td></t<>	5	hsa-mir-151a	dbDEMC	45
7hsa-mir-302bPhenomikTo8hsa-mir-106bdbDEMC,479hsa-mir-296dbDEMC,4810hsa-mir-296dbDEMC,4911hsa-mir-296dbDEMC,4912hsa-mir-122Phenomik5011hsa-mir-124phenomik5012hsa-mir-99adbDEMC,cancergen13hsa-mir-99adbDEMC,cancergen14hsa-mir-193bdbDEMC,cancergen15hsa-mir-708dbDEMCbiological16hsa-mir-378adbDEMC,confirmati17hsa-mir-378adbDEMC,confirmati18hsa-mir-625dbDEMC,The hig20hsa-mir-15bdbDEMC,The hig21hsa-mir-15bdbDEMC,dysregulat22hsa-mir-149dbDEMC,fied by bi23hsa-mir-328dbDEMC,mirRNAs, 424hsa-mir-129dbDEMC,are not congentik25hsa-mir-139dbDEMC,are not congentik26hsa-mir-139dbDEMC,are not congentik27hsa-mir-1302aPhenomikparticular28hsa-mir-134dbDEMC,cell-cycle29hsa-mir-134dbDEMC,confirmed30hsa-mir-134dbDEMC,confirmed31hsa-mir-320aPhenomikmirAs, 433hsa-mir-148bdbDEMC,confirmed34hsa-mir-148bdbDEMC, <td>6</td> <td>hsa-mir-130a</td> <td>dbDEMC,</td> <td></td>	6	hsa-mir-130a	dbDEMC,	
8 hsa-mir-106b dbDEMC, 47 9 hsa-mir-429 dbDEMC 48 10 hsa-mir-296 dbDEMC, 49 9 hsa-mir-296 dbDEMC, 49 11 hsa-mir-296 dbDEMC, 49 11 hsa-mir-112 PhenomiR 50 12 hsa-mir-451a dbDEMC, cancergen 13 hsa-mir-193b dbDEMC, cancergen 14 hsa-mir-708 dbDEMC, cancergen 15 hsa-mir-708 dbDEMC, prostate of phenomik 16 hsa-mir-378a dbDEMC, confirmation 17 hsa-mir-152 dbDEMC, confirmation 18 hsa-mir-204 dbDEMC, women. ³⁷ 20 hsa-mir-129 dbDEMC, dysregulate 21 hsa-mir-149 dbDEMC, mirNAs, 4 22 hsa-mir-204 dbDEMC, mirNAs, 4 23 hsa-mir-129 dbDEMC, mirNAs, 4 24 hsa-mir-328 dbDEMC, mirNAs, 4 25 hs			PhenomiR	46
Phenomikn9hsa-mir-296dbDEMC4810hsa-mir-296dbDEMC4911hsa-mir-122Phenomik5011hsa-mir-122Phenomik5012hsa-mir-122Phenomik5013hsa-mir-19adbDEMC1114hsa-mir-19abdbDEMC1115hsa-mir-708dbDEMCdifferentia16hsa-mir-378adbDEMCbiological17hsa-mir-378adbDEMCbiological18hsa-mir-152dbDEMClisted in T20hsa-mir-625dbDEMClisted in T21hsa-mir-15bdbDEMCdysregulat22hsa-mir-149dbDEMCdysregulat23hsa-mir-15bdbDEMCdysregulat24hsa-mir-129dbDEMCnomik 630 and h25hsa-mir-139dbDEMCare not co26hsa-mir-139dbDEMCare not co27hsa-mir-139dbDEMCsa are not co28hsa-mir-139dbDEMCsa at co29hsa-mir-130dbDEMCcountries, phenomik30hsa-mir-10adbDEMCcountries, phenomik31hsa-mir-30aPhenomikmir-630 ir33hsa-mir-149HbDEMCcountries, phenomik34hsa-mir-148bdbDEMCconfirmed35hsa-mir-151bdbDEMCconfirmed36hsa-mir-151bdbDEMCconfirmed36 <td>7</td> <td></td> <td>PhenomiR</td> <td></td>	7		PhenomiR	
9hsa-mir-29dbDEMC4810hsa-mir-296dbDEMC,4911hsa-mir-296phenomiR5011hsa-mir-122PhenomiR5012hsa-mir-451adbDEMC,cancergen13hsa-mir-99adbDEMC,cancergen14hsa-mir-193bdbDEMC,cancergen15hsa-mir-708dbDEMCdifferentia16hsa-mir-378adbDEMCbiological17hsa-mir-302cPhenomiRprostate of18hsa-mir-152dbDEMC,confirmati19hsa-mir-625dbDEMC,listed in T20hsa-mir-204dbDEMC,women. ³⁷ 21hsa-mir-15bdbDEMC,dysregulat22hsa-mir-149dbDEMC,dysregulat23hsa-mir-328dbDEMC,miRNAs a24hsa-mir-328dbDEMC,miRNAs a25hsa-mir-139dbDEMC,are not confirmati26hsa-mir-139dbDEMC,are not confirmati27hsa-mir-139dbDEMC,are not confirmati28hsa-mir-10adbDEMC,miRNAs a30hsa-mir-30adbDEMC,countries,31hsa-mir-30aPhenomiRmir-630 ir33hsa-mir-104dbDEMC,countries,34hsa-mir-14bdbDEMC,miRNAs.35hsa-mir-135PhenomiRassociation36hsa-mir-130dbDEMC,miRNAs.36hsa-mir-1	8	hsa-mir-106b	,	47
10hsa-mir-296dbDEMC, PhenomiR49 PhenomiR11hsa-mir-122PhenomiR5011hsa-mir-122PhenomiR5012hsa-mir-451adbDEMC1113hsa-mir-99adbDEMC, PhenomiRcancergen14hsa-mir-708dbDEMCdifferentia15hsa-mir-708dbDEMCbiological16hsa-mir-378adbDEMCbiological17hsa-mir-302cPhenomiRconfirmati19hsa-mir-625dbDEMC,confirmati20hsa-mir-152dbDEMC,confirmati21hsa-mir-15bdbDEMC,women. ³⁷ 22hsa-mir-15bdbDEMC,dysregulat23hsa-mir-328dbDEMC,fied by bi24hsa-mir-20bdbDEMC,miRNAs, 425hsa-mir-129dbDEMC,are not con26hsa-mir-139dbDEMC,are not con27hsa-mir-139dbDEMC,are not con28hsa-mir-139dbDEMC,silo and h29hsa-mir-10adbDEMC,silo and h30hsa-mir-30aPhenomiRmir-630 ir31hsa-mir-30aPhenomiRassociatio33hsa-mir-148bdbDEMC,mirKAs, a34hsa-mir-151bdbDEMC,confirmed35hsa-mir-151bdbDEMC,confirmed36hsa-mir-215PhenomiRand only36hsa-mir-215PhenomiRand only<				
Phenomik5011hsa-mir-122Phenomik12hsa-mir-451adbDEMC13hsa-mir-99adbDEMC,14hsa-mir-193bdbDEMC,15hsa-mir-708dbDEMC16hsa-mir-378adbDEMC17hsa-mir-378adbDEMC,18hsa-mir-152dbDEMC,19hsa-mir-625dbDEMC,10hsa-mir-204dbDEMC,20hsa-mir-15bdbDEMC,21hsa-mir-15bdbDEMC,22hsa-mir-120dbDEMC,23hsa-mir-328dbDEMC,24hsa-mir-204dbDEMC,25hsa-mir-328dbDEMC,26hsa-mir-139dbDEMC,27hsa-mir-129dbDEMC,28hsa-mir-139dbDEMC,29hsa-mir-149dbDEMC,20hsa-mir-32a21hsa-mir-32a22hsa-mir-32a23hsa-mir-32a24hsa-mir-13925hsa-mir-13926hsa-mir-13927hsa-mir-13928hsa-mir-10a29hsa-mir-10a20hsa-mir-10a21hsa-mir-30a22hsa-mir-10a23hsa-mir-13924hsa-mir-13925hsa-mir-13926hsa-mir-13027hsa-mir-13028hsa-mir-13029hsa-mir-302a20hsa-mir-302a21hsa-mir-302a				
11hsa-mir-122PhenomiR12hsa-mir-451adbDEMC13hsa-mir-99adbDEMC,14hsa-mir-193bdbDEMC,15hsa-mir-708dbDEMC16hsa-mir-378adbDEMC17hsa-mir-378adbDEMC18hsa-mir-378adbDEMC19hsa-mir-625dbDEMC19hsa-mir-625dbDEMC,20hsa-mir-15bdbDEMC,21hsa-mir-15bdbDEMC,22hsa-mir-149dbDEMC,23hsa-mir-204dbDEMC,24hsa-mir-205dbDEMC,25hsa-mir-206dbDEMC,26hsa-mir-139dbDEMC,27hsa-mir-139dbDEMC,28hsa-mir-139dbDEMC,29hsa-mir-10adbDEMC,29hsa-mir-302aPhenomiR20hsa-mir-302aPhenomiR21hsa-mir-139dbDEMC,22hsa-mir-149dbDEMC,23hsa-mir-139dbDEMC,24hsa-mir-139dbDEMC,25hsa-mir-139dbDEMC,26hsa-mir-139dbDEMC,27hsa-mir-302aPhenomiR28hsa-mir-134dbDEMC,30hsa-mir-304PhenomiR31hsa-mir-304PhenomiR32hsa-mir-139dbDEMC,33hsa-mir-130dbDEMC,34hsa-mir-130dbDEMC,35hsa-mir-130dbDEMC,36 <td>10</td> <td>hsa-mir-296</td> <td></td> <td></td>	10	hsa-mir-296		
12 hsa-mir-451a dbDEMC, 13 hsa-mir-99a dbDEMC, 14 hsa-mir-193b dbDEMC, 15 hsa-mir-708 dbDEMC 16 hsa-mir-378a dbDEMC 17 hsa-mir-302c PhenomiR 18 hsa-mir-302c PhenomiR 19 hsa-mir-625 dbDEMC, 19 hsa-mir-204 dbDEMC, 20 hsa-mir-15b dbDEMC, 21 hsa-mir-149 dbDEMC, 22 hsa-mir-149 dbDEMC, 23 hsa-mir-204 dbDEMC, 24 hsa-mir-328 dbDEMC, 25 hsa-mir-20b dbDEMC, 26 hsa-mir-139 dbDEMC, 27 hsa-mir-139 dbDEMC, 28 hsa-mir-139 dbDEMC, 29 hsa-mir-1302a PhenomiR 29 hsa-mir-302a PhenomiR 20 hsa-mir-302a PhenomiR 29 hsa-mir-302a PhenomiR 29 hsa-mir-302a PhenomiR <t< td=""><td>11</td><td>h</td><td></td><td>50</td></t<>	11	h		50
13hsa-mir-99adbDEMC, PhenomiR14hsa-mir-193bdbDEMC, PhenomiRcancergen PhenomiR15hsa-mir-708dbDEMCdifferentia differentia16hsa-mir-378adbDEMCbiological17hsa-mir-378adbDEMCbiological18hsa-mir-152dbDEMC, PhenomiRprostate of PhenomiR19hsa-mir-625dbDEMC, PhenomiRconfirmati PhenomiR20hsa-mir-625dbDEMC, PhenomiRwomen.a21hsa-mir-15bdbDEMC, PhenomiRwomen.a22hsa-mir-149dbDEMC, PhenomiRdysregulat PhenomiR23hsa-mir-204dbDEMC, PhenomiRfied by bi PhenomiR24hsa-mir-205dbDEMC, PhenomiRmiRNAs, 4 PhenomiR25hsa-mir-129dbDEMC, PhenomiRare not con PhenomiR26hsa-mir-139dbDEMC, PhenomiRare not con PhenomiR27hsa-mir-302aPhenomiR PhenomiRmir-630 in 				
14hsa-mir-193bPhenomiR dbDEMC, PhenomiR PhenomiR dbDEMCcancergen studies, t15hsa-mir-708dbDEMCdifferentia16hsa-mir-378adbDEMCbiological17hsa-mir-302cPhenomiR PhenomiRprostate c18hsa-mir-152dbDEMC, PhenomiRconfirmati19hsa-mir-625dbDEMClisted in T20hsa-mir-15bdbDEMC, PhenomiRcommon d21hsa-mir-15bdbDEMC, PhenomiRdysregulat22hsa-mir-149dbDEMC, PhenomiRdysregulat23hsa-mir-328dbDEMC, PhenomiRmiRNAs, a24hsa-mir-20bdbDEMC, PhenomiRmiRNAs, a25hsa-mir-129dbDEMC, PhenomiRmiRNAs, a26hsa-mir-139dbDEMC, PhenomiRare not com27hsa-mir-302aPhenomiR PhenomiRmir-630 ir28hsa-mir-302aPhenomiR PhenomiRprostat30hsa-mir-302aPhenomiR PhenomiRProstat31hsa-mir-302aPhenomiR PhenomiRBiologi33hsa-mir-148bdbDEMC, PhenomiRcountries, PhenomiR34hsa-mir-148bdbDEMC, PhenomiRmirAs. J PhenomiR35hsa-mir-148bdbDEMC, PhenomiRmirAs. J PhenomiR36hsa-mir-151bdbDEMC, PhenomiRconfirmed PhenomiR36hsa-mir-151bdbDEMC, PhenomiRconfirmed PhenomiR36hsa-mir-				
14hsa-mir-193bdbDEMC, PhenomiRcancergen PhenomiR15hsa-mir-708dbDEMCdifferentia16hsa-mir-378adbDEMCbiological16hsa-mir-378adbDEMCbiological17hsa-mir-302cPhenomiRconfirmati18hsa-mir-152dbDEMC,confirmati19hsa-mir-204dbDEMC,The hip20hsa-mir-204dbDEMC,women. ³⁷ 21hsa-mir-15bdbDEMC,dysregulat22hsa-mir-149dbDEMC,dysregulat23hsa-mir-204dbDEMC,fied by bi24hsa-mir-20bPhenomiRmiRNAs, 425hsa-mir-129dbDEMC,nomiR da26hsa-mir-139dbDEMC,are not con27hsa-mir-302aPhenomiRparticulari28hsa-mir-10adbDEMC,fied by bi29hsa-mir-10adbDEMC,fiel are not con29hsa-mir-149dbDEMC,fiel are not con20hsa-mir-148dbDEMC,fiel are not con21hsa-mir-148dbDEMC,fiel are not con23hsa-mir-148dbDEMC,fiel are not con24hsa-mir-139dbDEMC,fiel are not con25hsa-mir-148dbDEMC,fiel are not con26hsa-mir-139dbDEMC,fiel are not con27hsa-mir-148dbDEMC,fiel are not con28hsa-mir-148dbDEMC,fiel are not con	15	115a-1111-39a	,	
PhenomiR studies, t 15 hsa-mir-708 dbDEMC differentia 16 hsa-mir-378a dbDEMC biological 17 hsa-mir-302c PhenomiR prostate c PhenomiR confirmati 19 hsa-mir-625 dbDEMC, The hi PhenomiR common 19 hsa-mir-15b dbDEMC, The hi PhenomiR common 21 hsa-mir-15b dbDEMC, dysregulat PhenomiR benchmar 22 hsa-mir-149 dbDEMC, fied by bi PhenomiR miRNAs a 24 hsa-mir-206 dbDEMC, moriR da 25 hsa-mir-129 dbDEMC, are not co PhenomiR 630 and h 26 hsa-mir-139 dbDEMC, are not co PhenomiR particular 27 hsa-mir-139 dbDEMC, are not co PhenomiR particular 28 hsa-mir-302a PhenomiR mir-630 ir 29 hsa-mir-304 dbDEMC, countries, 30 hsa-mir-304 dbDEMC, silon are not co PhenomiR particular 31 hsa-mir-304 dbDEMC, countries, 33 hsa-mir-304 dbDEMC, countries, 34 hsa-mir-304 PhenomiR associatio 33 hsa-mir-304 PhenomiR associatio 34 hsa-mir-304 PhenomiR associatio 35 hsa-mir-148 dbDEMC, confirmed PhenomiR and only 36 hsa-mir-151b dbDEMC, confirmed PhenomiR and only 36 hsa-mir-151b dbDEMC, confirmed PhenomiR and only 36 hsa-mir-151b dbDEMC, confirmed PhenomiR and only 36 hsa-mir-99b dbDEMC, the two da	14	hsa-mir-193h		cancergen
16hsa-mir-378adbDEMCbiological17hsa-mir-302cPhenomiRprostate of18hsa-mir-152dbDEMC,confirmati19hsa-mir-625dbDEMClisted in T20hsa-mir-204dbDEMC,The hig20hsa-mir-15bPhenomiRcommon d21hsa-mir-149dbDEMC,dysregulat22hsa-mir-149dbDEMC,field by bi23hsa-mir-328dbDEMC,field by bi24hsa-mir-20bdbDEMC,miRNAs, a25hsa-mir-129dbDEMC,nomiR26hsa-mir-139dbDEMC,nomiR27hsa-mir-302aPhenomiRparticular28hsa-mir-194dbDEMC,cell-cycle I29hsa-mir-302aPhenomiRpricolar30hsa-mir-302aPhenomiRsociation31hsa-mir-302aPhenomiRprostat33hsa-mir-194dbDEMC,countries,34hsa-mir-196bdbDEMC,countries,35hsa-mir-1975PhenomiRassociation36hsa-mir-151bdbDEMC,confirmed37hsa-mir-99bdbDEMC,the two data		insu inin 1900	,	studies, t
16hsa-mir-378adbDEMCbiological17hsa-mir-302cPhenomiRprostate of18hsa-mir-152dbDEMC,confirmati19hsa-mir-625dbDEMClisted in T20hsa-mir-204dbDEMC,The hig20hsa-mir-15bPhenomiRcommon d21hsa-mir-16PhenomiRcommon d22hsa-mir-149dbDEMC,dysregulat23hsa-mir-328dbDEMC,field by bi24hsa-mir-20bdbDEMC,miRNAs, a25hsa-mir-129dbDEMC,nomiR26hsa-mir-129dbDEMC,nomiR27hsa-mir-302aPhenomiRparticular28hsa-mir-194dbDEMC,cell-cycle I29hsa-mir-302aPhenomiRparticular30hsa-mir-302aPhenomiRsociation31hsa-mir-302aPhenomiRBiologi33hsa-mir-194dbDEMC,countries,34hsa-mir-196bdbDEMC,countries,35hsa-mir-196bdbDEMC,confirmed36hsa-mir-151bdbDEMC,confirmed36hsa-mir-151bdbDEMC,confirmed36hsa-mir-151bdbDEMC,confirmed37hsa-mir-99bdbDEMC,the two data	15	hsa-mir-708	dbDEMC	differentia
17hsa-mir-302cPhenomiRprostate c18hsa-mir-152dbDEMC,confirmati19hsa-mir-625dbDEMClisted in T20hsa-mir-204dbDEMC,The hig21hsa-mir-15bdbDEMC,women. ³⁷ 22hsa-mir-149dbDEMC,dysregulat23hsa-mir-328dbDEMC,field by bi24hsa-mir-20bdbDEMC,miRNAs, a25hsa-mir-129dbDEMC,nomiR26hsa-mir-139dbDEMC,are not con27hsa-mir-302aPhenomiRparticular28hsa-mir-194dbDEMC,are not con29hsa-mir-302aPhenomiRmir-630 ir30hsa-mir-304dbDEMC,countries,31hsa-mir-302aPhenomiRBiologi32hsa-mir-10adbDEMC,countries,33hsa-mir-148bdbDEMC,countries,34hsa-mir-151bdbDEMC,confirmed35hsa-mir-151bdbDEMC,confirmed36hsa-mir-151bdbDEMC,confirmed37hsa-mir-151bdbDEMC,the wode	16	hsa-mir-378a	dbDEMC	
18 hsa-mir-152 dbDEMC, confirmati 19 hsa-mir-625 dbDEMC listed in T 20 hsa-mir-204 dbDEMC, The hig 20 hsa-mir-15b dbDEMC, women. ³⁷ 21 hsa-mir-15b dbDEMC, women. ³⁷ 22 hsa-mir-149 dbDEMC, dysregulat 23 hsa-mir-328 dbDEMC, field by bi 24 hsa-mir-20b dbDEMC, miRNAs, a 25 hsa-mir-129 dbDEMC, nomiR da 26 hsa-mir-139 dbDEMC, are not com 27 hsa-mir-139 dbDEMC, are not com 28 hsa-mir-194 dbDEMC, 519c as at 29 hsa-mir-194 dbDEMC, countries, PhenomiR 30 hsa-mir-302a PhenomiR 31 hsa-mir-302a PhenomiR 32 hsa-mir-194 dbDEMC, countries, PhenomiR 33 hsa-mir-302a PhenomiR 34 hsa-mir-302a PhenomiR 35 hsa-mir-194 dbDEMC, countries, PhenomiR 36 hsa-mir-194 dbDEMC, countries, PhenomiR 33 hsa-mir-148b <	17	hsa-mir-302c	PhenomiR	e
19hsa-mir-625dbDEMClisted in T20hsa-mir-204dbDEMC,The hig21hsa-mir-15bdbDEMC,women. ³⁷ 22hsa-mir-149dbDEMC,dysregulat23hsa-mir-328dbDEMC,field by bi24hsa-mir-20bdbDEMC,miRNAs, a25hsa-mir-129dbDEMC,are not con26hsa-mir-139dbDEMC,are not con27hsa-mir-302aPhenomiRparticular27hsa-mir-194dbDEMC,mir-630 ir28hsa-mir-10adbDEMC,sa at phenomiR29hsa-mir-320aPhenomiRProstat30hsa-mir-320adbDEMC,countries,31hsa-mir-320adbDEMC,countries,33hsa-mir-148bdbDEMC,miRNAs.34hsa-mir-148bdbDEMC,confirmed35hsa-mir-151bdbDEMC,g2b, ranka36hsa-mir-151bdbDEMC,the two da	18	hsa-mir-152	dbDEMC,	-
20hsa-mir-204dbDEMC, PhenomiRThe hig PhenomiR21hsa-mir-15bdbDEMC, PhenomiRwomen.37 PhenomiR22hsa-mir-149dbDEMC, PhenomiRdysregulat PhenomiR23hsa-mir-328dbDEMC, PhenomiRfield by bi PhenomiR24hsa-mir-20bdbDEMC, PhenomiRmiRNAs, a PhenomiR25hsa-mir-129dbDEMC, PhenomiRnomiR da PhenomiR26hsa-mir-139dbDEMC, PhenomiRare not con PhenomiR27hsa-mir-302aPhenomiR PhenomiRmir-630 ir PhenomiR29hsa-mir-10adbDEMC, PhenomiR519c as a t PhenomiR30hsa-mir-302aPhenomiR PhenomiRProstat Biologi31hsa-mir-302adbDEMC, PhenomiRcountries, PhenomiR33hsa-mir-10adbDEMC, PhenomiRcountries, PhenomiR34hsa-mir-449aPhenomiR PhenomiRassociation PhenomiR34hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR35hsa-mir-151bdbDEMC, PhenomiRconfirmed PhenomiR36hsa-mir-151bdbDEMC, PhenomiRconfirmed PhenomiR			PhenomiR	
21hsa-mir-15bPhenomiRcommon of women.37 22 hsa-mir-149dbDEMC, PhenomiRdysregulat benchmar 23 hsa-mir-328dbDEMC, PhenomiRfied by bi PhenomiR 24 hsa-mir-20bdbDEMC, PhenomiRmiRNAs a PhenomiR 24 hsa-mir-129dbDEMC, PhenomiRmiRNAs, a PhenomiR 25 hsa-mir-129dbDEMC, PhenomiRare not complexity 26 hsa-mir-302aPhenomiR PhenomiRparticular mir-630 in PhenomiR 27 hsa-mir-10adbDEMC, PhenomiR519c as a t PhenomiR 29 hsa-mir-10adbDEMC, 	19			
21hsa-mir-15bdbDEMC, PhenomiRwomen.37 women.3722hsa-mir-149dbDEMC, PhenomiRdysregulat PhenomiR23hsa-mir-328dbDEMC, PhenomiRfield by bi PhenomiR24hsa-mir-20bdbDEMC, PhenomiRmiRNAs, 4 PhenomiR25hsa-mir-129dbDEMC, PhenomiRnomiR da PhenomiR26hsa-mir-139dbDEMC, PhenomiRare not con PhenomiR27hsa-mir-302aPhenomiR PhenomiRmir-630 ir PhenomiR29hsa-mir-10adbDEMC, PhenomiRcell-cycle I PhenomiR30hsa-mir-320adbDEMC, PhenomiRcountries, PhenomiR31hsa-mir-449aPhenomiR PhenomiRBiologi Biologi33hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR34hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR35hsa-mir-151bdbDEMC, PhenomiRconfirmed PhenomiR36hsa-mir-151bdbDEMC, PhenomiRcharter-relation PhenomiR	20	hsa-mir-204	,	The hig
PhenomiR Women." PhenomiR dysregulat PhenomiR benchmar PhenomiR benchmar PhenomiR benchmar PhenomiR benchmar PhenomiR miRNAs a PhenomiR miRNAs a PhenomiR miRNAs, 4 PhenomiR nomiR da PhenomiR 630 and h PhenomiR 630 and h PhenomiR particularl PhenomiR mir-630 ir PhenomiR cell-cycle I PhenomiR Prostat PhenomiR Prostat PhenomiR Biologi PhenomiR Biologi PhenomiR Biologi PhenomiR Biologi PhenomiR Biologi PhenomiR association PhenomiR and only PhenomiR and only PhenomiR and only PhenomiR ash-mir-151b dbDEMC, the two da				common o
22hsa-mir-149dbDEMC, PhenomiRdysregulat benchmar23hsa-mir-328dbDEMC, PhenomiRfied by bi PhenomiR24hsa-mir-20bdbDEMC, PhenomiRmiRNAs, 4 PhenomiR25hsa-mir-129dbDEMC, PhenomiRnomiR da PhenomiR26hsa-mir-139dbDEMC, PhenomiRare not con PhenomiR27hsa-mir-302aPhenomiR PhenomiRmir-630 ir PhenomiR29hsa-mir-104dbDEMC, PhenomiRcell-cycle I PhenomiR30hsa-mir-302aPhenomiR PhenomiRProstat PhenomiR31hsa-mir-304PhenomiR PhenomiRBiologi Biologi33hsa-mir-148bdbDEMC, PhenomiRcancer-relation34hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR35hsa-mir-215PhenomiR PhenomiRand only Safa36hsa-mir-151bdbDEMC, PhenomiRconfirmed PhenomiR	21	hsa-mir-15b	,	women.37
22Itsamin-14.9dbDEMC, phenomikbenchmar benchmar23hsa-mir-32.8dbDEMC, phenomikfied by bi phenomik24hsa-mir-20bdbDEMC, phenomikmiRNAs, 4 miRNAs, 425hsa-mir-129dbDEMC, phenomiknomiR da phenomik26hsa-mir-139dbDEMC, phenomikare not con phenomik27hsa-mir-302aphenomik phenomikmir-630 ir mir-630 ir phenomik29hsa-mir-10adbDEMC, phenomikcell-cycle I phenomik30hsa-mir-320adbDEMC, phenomikcountries, phenomik31hsa-mir-449aphenomik phenomikBiologi as action33hsa-mir-194dbDEMC, phenomikmirNAs. I phenomik34hsa-mir-148bdbDEMC, phenomikconfirmed phenomik35hsa-mir-151bdbDEMC, phenomikconfirmed phenomik36hsa-mir-99bdbDEMC, the two da	22	h		dysregulat
23 hsa-mir-328 dbDEMC, fied by bi PhenomiR miRNAs a PhenomiR miRNAs a 24 hsa-mir-20b dbDEMC, miRNAs, 4 PhenomiR nomiR da PhenomiR 630 and h 25 hsa-mir-139 dbDEMC, are not cou PhenomiR particularl 27 hsa-mir-302a PhenomiR mir-630 ir 28 hsa-mir-194 dbDEMC, cell-cycle I 29 hsa-mir-10a dbDEMC, 519c as a t PhenomiR Prostat 30 hsa-mir-320a dbDEMC, countries, PhenomiR Biologi 31 hsa-mir-449a PhenomiR association 33 hsa-mir-196b dbDEMC, miRNAs. I PhenomiR cancer-rela 34 hsa-mir-148b dbDEMC, confirmed PhenomiR and only 35 hsa-mir-151b dbDEMC, the two da 37 hsa-mir-99b dbDEMC, the two da	22	nsa-mir-149	,	
24hsa-mir-20bPhenomiRmiRNAs a25hsa-mir-129dbDEMC,miRNAs, 425hsa-mir-129dbDEMC,nomiR da26hsa-mir-139dbDEMC,are not con27hsa-mir-302aPhenomiRparticularl28hsa-mir-194dbDEMC,cell-cycle I29hsa-mir-10adbDEMC,519c as a t30hsa-mir-302aPhenomiRProstat31hsa-mir-302aPhenomiRBiologi32hsa-mir-10adbDEMC,countries,33hsa-mir-302dPhenomiRBiologi34hsa-mir-148bdbDEMC,confirmed35hsa-mir-151bdbDEMC,confirmed36hsa-mir-151bdbDEMC,yeb, ranka37hsa-mir-99bdbDEMC,the two da	23	hsa-mir-328		
24hsa-mir-20bdbDEMC, PhenomiRmiRNAs, 4 miRNAs, 425hsa-mir-129dbDEMC, PhenomiRnomiR da of and h26hsa-mir-139dbDEMC, PhenomiRare not con phenomiR27hsa-mir-302aPhenomiR PhenomiRmir-630 ir mir-630 ir PhenomiR28hsa-mir-194dbDEMC, PhenomiRcell-cycle I PhenomiR29hsa-mir-10adbDEMC, PhenomiR519c as a t PhenomiR30hsa-mir-320adbDEMC, PhenomiRcountries, PhenomiR31hsa-mir-449aPhenomiR PhenomiRBiologi association33hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR34hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR35hsa-mir-215PhenomiR PhenomiRand only36hsa-mir-99bdbDEMC, the two da	23	1150 1111 520	/	v
PhenomiR miRNAS, 2 25 hsa-mir-129 dbDEMC, nomiR da 26 hsa-mir-139 dbDEMC, are not cor PhenomiR particular 27 hsa-mir-302a PhenomiR mir-630 ir 28 hsa-mir-194 dbDEMC, cell-cycle I 29 hsa-mir-10a dbDEMC, 519c as a t PhenomiR Prostat 30 hsa-mir-320a dbDEMC, countries, PhenomiR Biologi 31 hsa-mir-449a PhenomiR association 32 hsa-mir-196b dbDEMC, miRNAS, I PhenomiR cancer-rela 34 hsa-mir-148b dbDEMC, confirmed PhenomiR and only 35 hsa-mir-215 PhenomiR and only 36 hsa-mir-151b dbDEMC, the two da 37 hsa-mir-99b dbDEMC, the two da	24	hsa-mir-20b		
25nsa-mir-129dbDEMC, PhenomiR630 and h26hsa-mir-139dbDEMC, PhenomiRare not com PhenomiR27hsa-mir-302aPhenomiRmir-630 in PhenomiR28hsa-mir-194dbDEMC, PhenomiRcell-cycle I PhenomiR29hsa-mir-10adbDEMC, PhenomiR519c as a t PhenomiR30hsa-mir-320adbDEMC, PhenomiRcountries, PhenomiR31hsa-mir-449aPhenomiR PhenomiRBiologi Biologi Biologi Biologi33hsa-mir-196bdbDEMC, PhenomiRmiRNAs. I PhenomiR34hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR35hsa-mir-215 Sha-mir-151bPhenomiR BioDEMC, PhenomiRgod, confirmed PhenomiR36hsa-mir-99bdbDEMC, BioDEMC,the two da			/	
26hsa-mir-139dbDEMC, PhenomiRare not con particular27hsa-mir-302aPhenomiRparticular28hsa-mir-194dbDEMC, PhenomiRcell-cycle I29hsa-mir-10adbDEMC, PhenomiR519c as a t Prostat30hsa-mir-320adbDEMC, PhenomiRcountries, PhenomiR31hsa-mir-449aPhenomiR PhenomiRBiologi32hsa-mir-106bdbDEMC, PhenomiRmiRNAs. I PhenomiR33hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR34hsa-mir-215PhenomiR PhenomiRand only35hsa-mir-151bdbDEMC, PhenomiR92b, ranke PhenomiR	25	hsa-mir-129	dbDEMC,	
PhenomiR particular hsa-mir-302a PhenomiR mir-630 ir hsa-mir-194 dbDEMC, cell-cycle I PhenomiR cell-cycle I PhenomiR Prostat hsa-mir-320a dbDEMC, countries, PhenomiR Biologi hsa-mir-449a PhenomiR Biologi hsa-mir-302d PhenomiR association hsa-mir-196b dbDEMC, miRNAs. I PhenomiR cancer-rela hsa-mir-148b dbDEMC, confirmed PhenomiR and only hsa-mir-215 PhenomiR and only hsa-mir-151b dbDEMC, the two da phenomiR 22b, ranked			PhenomiR	630 and h
27hsa-mir-302aPhenomiRphenotian28hsa-mir-194dbDEMC, PhenomiRcell-cycle I29hsa-mir-10adbDEMC, PhenomiR519c as a t30hsa-mir-320adbDEMC, PhenomiRcountries, PhenomiR31hsa-mir-449aPhenomiRBiologi32hsa-mir-302dPhenomiRassociation33hsa-mir-196bdbDEMC, PhenomiRconfirmed34hsa-mir-148bdbDEMC, PhenomiRconfirmed35hsa-mir-215PhenomiRand only36hsa-mir-151bdbDEMC, PhenomiR92b, ranked37hsa-mir-99bdbDEMC, the two da	26	hsa-mir-139	dbDEMC,	are not con
27hsa-mir-302aPhenomikmir-630 ir28hsa-mir-194dbDEMC, Phenomikcell-cycle I29hsa-mir-10adbDEMC, Phenomik519c as a t30hsa-mir-320adbDEMC, Phenomikcountries, Phenomik31hsa-mir-449aPhenomikBiologi32hsa-mir-302dPhenomikassociation33hsa-mir-196bdbDEMC, Phenomikconfirmed34hsa-mir-148bdbDEMC, Phenomikconfirmed35hsa-mir-215Phenomik Phenomikand only36hsa-mir-151bdbDEMC, Phenomik92b, ranke37hsa-mir-99bdbDEMC, Phenomikthe two da			PhenomiR	particularl
28hsa-mir-194dbDEMC, PhenomiRcell-cycle I PhenomiR29hsa-mir-10adbDEMC, PhenomiR519c as a t PhenomiR30hsa-mir-320adbDEMC, PhenomiRcountries, Biologi31hsa-mir-449aPhenomiRBiologi32hsa-mir-302dPhenomiRassociation PhenomiR33hsa-mir-196bdbDEMC, PhenomiRconfirmed PhenomiR34hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR35hsa-mir-215PhenomiRand only36hsa-mir-151bdbDEMC, PhenomiR92b, ranko PhenomiR37hsa-mir-99bdbDEMC, PhenomiRthe two da	27			
29 hsa-mir-10a dbDEMC, 519c as a t PhenomiR Prostat 30 hsa-mir-320a dbDEMC, countries, PhenomiR Biologi 31 hsa-mir-449a PhenomiR Biologi 32 hsa-mir-302d PhenomiR association 33 hsa-mir-196b dbDEMC, miRNAs. I PhenomiR cancer-rela 34 hsa-mir-148b dbDEMC, confirmed PhenomiR and only 35 hsa-mir-215 PhenomiR 92b, ranke 36 hsa-mir-151b dbDEMC, the two da	28	hsa-mir-194		
25Itsu mir fouab DEMC, PhenomiRProstat Prostat30hsa-mir-320adbDEMC, PhenomiRcountries, Biologi31hsa-mir-449aPhenomiRBiologi32hsa-mir-302dPhenomiRassociation33hsa-mir-196bdbDEMC, PhenomiRcancer-relation34hsa-mir-148bdbDEMC, PhenomiRconfirmed PhenomiR35hsa-mir-215PhenomiRand only36hsa-mir-151bdbDEMC, the two dache two da37hsa-mir-99bdbDEMC,the two da		1		•
30hsa-mir-320adbDEMC, PhenomiRcountries, Biologi31hsa-mir-449aPhenomiRBiologi32hsa-mir-302dPhenomiRassociation33hsa-mir-196bdbDEMC,miRNAs.34hsa-mir-148bdbDEMC,confirmed35hsa-mir-215PhenomiRand only36hsa-mir-151bdbDEMC,yeb, ranke37hsa-mir-99bdbDEMC,the two da	29	hsa-mir-10a	,	
Phenomik Biologi 31 hsa-mir-449a Phenomik Biologi 32 hsa-mir-302d Phenomik association 33 hsa-mir-196b dbDEMC, miRNAs. I Phenomik cancer-rela 34 hsa-mir-148b dbDEMC, confirmed Phenomik and only 35 hsa-mir-215 Phenomik 92b, ranke 36 hsa-mir-151b dbDEMC 92b, ranke 37 hsa-mir-99b dbDEMC, the two da	20	h		
31hsa-mir-449aPhenomiRBiologi32hsa-mir-302dPhenomiRassociation33hsa-mir-196bdbDEMC,miRNAs.34hsa-mir-148bdbDEMC,confirmed35hsa-mir-215PhenomiRand only36hsa-mir-151bdbDEMC,92b, ranke37hsa-mir-99bdbDEMC,the two data	30	nsa-mir-320a		
32hsa-mir-302dPhenomiRassociation33hsa-mir-196bdbDEMC,miRNAs.34hsa-mir-148bdbDEMC,confirmed35hsa-mir-215PhenomiRand only36hsa-mir-151bdbDEMC92b, ranke37hsa-mir-99bdbDEMC,the two da	31	hsa-mir-149a		Biologi
33hsa-mir-196bdbDEMC,miRNAs. 134hsa-mir-148bdbDEMC,concer-rela35hsa-mir-215PhenomiRand only36hsa-mir-151bdbDEMC92b, ranke37hsa-mir-99bdbDEMC,the two da				association
Phenomikcancer-rela34hsa-mir-148bdbDEMC, Phenomikconfirmed and only35hsa-mir-215Phenomik Phenomikand only36hsa-mir-151bdbDEMC92b, ranke the two da37hsa-mir-99bdbDEMC,the two da				miRNAs. 1
34hsa-mir-148bdbDEMC, PhenomiRconfirmed and only35hsa-mir-215PhenomiRand only36hsa-mir-151bdbDEMC92b, ranke37hsa-mir-99bdbDEMC,the two data			,	cancer-rela
PhenomiR and only 35 hsa-mir-215 PhenomiR 20, ranke 36 hsa-mir-151b dbDEMC 92b, ranke 37 hsa-mir-99b dbDEMC, the two da	34	hsa-mir-148b		
35hsa-mir-215PhenomiRand only36hsa-mir-151bdbDEMC92b, ranke37hsa-mir-99bdbDEMC,the two da				
37 hsa-mir-99b dbDEMC, the two da	35	hsa-mir-215		•
	36	hsa-mir-151b	dbDEMC	
PhenomiR hsa-mir-42	37	hsa-mir-99b		
			PhenomiR	hsa-mir-42

ank	miRNA	Evidences
8	hsa-mir-452	dbDEMC,
		PhenomiR
9	hsa-mir-367	PhenomiR
D	hsa-mir-342	dbDEMC,
		PhenomiR
L	hsa-mir-373	PhenomiR
2	hsa-mir-345	dbDEMC,
		PhenomiR
1	hsa-mir-449b	PhenomiR
1	hsa-mir-339	dbDEMC,
		PhenomiR
	hsa-mir-425	dbDEMC,
		PhenomiR
5	hsa-mir-23b	dbDEMC,
		PhenomiR
7	hsa-mir-130b	dbDEMC,
		PhenomiR
	hsa-mir-211	PhenomiR
	hsa-mir-92b	PhenomiR
	hsa-mir-181d	dbDEMC,

cancergenome.nih.gov/). By collecting data from published studies, the PhenomiR database provides information on differentially regulated miRNA expression in diseases and other biological processes. The top 50 potential lung cancer- and prostate cancer-related miRNAs predicted by NetCF and the confirmation by the dbDEMC and PhenomiR databases are listed in Tables 1 and 2.

The high mortality rate of lung cancer makes it the most common cause of cancer-related death in men and second in women.³⁷ Many researchers have demonstrated that miRNA dysregulation is associated with lung cancer, and in the benchmark dataset, 128 lung cancer-related miRNAs are verified by biological experiments. Unknown lung cancer-related miRNAs are predicted by NetCF. Among the top 50 predicted miRNAs, 47 of them are confirmed by the dbDEMC and PhenomiR databases; and only 3 miRNAs (hsa-mir-520g, hsa-mir-630 and hsa-mir-519c, ranked 41st, 47th and 49th, respectively) are not confirmed. The confirmation of the top 40 predictions is particularly gratifying. Moreover, Cao *et al.*³⁸ reported that hasmir-630 inhibits cell proliferation of lung cancer by targeting cell-cycle kinase 7 (CDC7); and Cha *et al.*³⁹ identified has-mir-519c as a tumor suppressor involved in lung cancer progression.

Prostate cancer is the most common cancer in males in 84 countries,³⁷ occurring more commonly in the developed world.

Biological experiments have demonstrated several important associations between prostate cancer and dysregulation of miRNAs. NetCF is implemented to predict potential prostate cancer-related miRNAs. Of the top 50 predicted miRNAs, 47 are confirmed based on the dbDEMC and PhenomiR databases; and only 3 miRNAs (hsa-mir-429, hsa-mir-449b and hsa-mir-92b, ranked third, 37th and 43rd, respectively) are not found in the two databases. Further literature search demonstrated that hsa-mir-429 inhibits cell proliferation by targeting p27Kip1 in human prostate cancer cells.⁴⁰

Rank	miRNA	Evidences
1	hsa-mir-18a	dbDEMC,
-	indu inin 10u	PhenomiR
2	hsa-mir-155	PhenomiR
3	hsa-mir-19a	dbDEMC,
		PhenomiR
4	hsa-mir-9	dbDEMC,
		PhenomiR
5	hsa-mir-10b	PhenomiR
6	hsa-mir-210	dbDEMC,
		PhenomiR
7	hsa-mir-19b	dbDEMC,
		PhenomiR
8	hsa-mir-181a	dbDEMC,
		PhenomiR
9	hsa-mir-7	dbDEMC,
		PhenomiR
10	hsa-mir-138	PhenomiR
11	hsa-mir-196a	dbDEMC,
		PhenomiR
12	hsa-mir-24	dbDEMC,
		PhenomiR
13	hsa-mir-142	PhenomiR
14	hsa-mir-29c	dbDEMC,
		PhenomiR
15	hsa-mir-30a	dbDEMC,
		PhenomiR
16	hsa-mir-125a	dbDEMC,
		PhenomiR
17	hsa-mir-302b	PhenomiR
18	hsa-mir-199b	dbDEMC,
		PhenomiR
19	hsa-let-7i	dbDEMC,
		PhenomiR
20	hsa-let-7g	dbDEMC,
	1 1	PhenomiR
21	hsa-let-7e	dbDEMC,
	1	PhenomiR
22	hsa-mir-499a	Unconfirmed
23	hsa-mir-150	PhenomiR
24	hsa-mir-429	Unconfirmed
25	hsa-mir-135a	dbDEMC,
26	hsa-let-7f	PhenomiR
26	nsa-let-/f	dbDEMC,
07	has min 451a	PhenomiR
27	hsa-mir-451a	dbDEMC
28	hsa-mir-192	dbDEMC
29	hsa-mir-302c hsa-mir-18b	PhenomiR
30 31	hsa-mir-139	dbDEMC
51	1158-1111-139	dbDEMC,
20	hsa-mir-103a	PhenomiR
32 33	hsa-mir-103a	dbDEMC dbDEMC
33 34	hsa-mir-625 hsa-mir-140	dbDEMC
34 35	hsa-mir-20b	dbDEMC
	hsa-mir-200 hsa-mir-215	
36	115a-11111-215	dbDEMC, PhenomiR
27	hsa-mir-128	dbDEMC,
37	115a-11111-128	PhenomiR
38	hsa-mir-129	dbDEMC,
50	115a-1111-129	PhenomiR
		PHEHOIIIIR

Table 4 (Contd.)

Rank	miRNA	Evidences
9	hsa-mir-137	PhenomiR
0	hsa-mir-302a	PhenomiR
1	hsa-mir-10a	dbDEMC,
		PhenomiR
2	hsa-mir-149	dbDEMC,
		PhenomiR
3	hsa-mir-26b	dbDEMC,
		PhenomiR
4	hsa-mir-328	dbDEMC,
		PhenomiR
5	hsa-mir-497	dbDEMC,
		PhenomiR
5	hsa-mir-30b	dbDEMC,
		PhenomiR
7	hsa-mir-302d	PhenomiR
8	hsa-mir-542	dbDEMC
Ð	hsa-mir-342	dbDEMC,
		PhenomiR
)	hsa-mir-338	dbDEMC,
		PhenomiR

3.4. Application of NetCF to predict isolated disease-related miRNAs

An isolated disease refers to a disease without any known associated miRNA. To further evaluate the predicted performance of NetCF for predicting isolated disease-related miRNAs, the recommended scores of potential associations are calculated by removing all known associations related to predicted disease. In other words, we only use the similarity information and known associations of other diseases to predict isolated disease-related miRNAs. Isolated disease-related miRNAs prediction is implemented for lung and prostate cancers with the top 50 potential miRNAs are listed in Tables 3 and 4, respectively. For lung cancer, all top 50 predicted miRNAs are confirmed based on the dbDEMC and PhenomiR databases. For prostate cancer, only 2 miRNAs (hsa-mir-499a and hsa-mir-429, ranked 22nd and 24th) of top 50 predicted results are not found in the two databases; and hsa-mir-429 is confirmed to be associated with prostate cancer by recently published literature.40 Acording to the above description, NetCF exhibits good performance for predicting potential miRNA-disease associations and isolated disease-related miRNAs.

4. Conclusions

Accumulative evidence has indicated that miRNAs play important roles in the pathogenesis and development of many complex diseases. The identification of novel disease-associated miRNAs is an important task in biomedical research, and it is beneficial for an in-depth understanding of disease mechanisms at the miRNA level. As a useful supplement to experimental studies, using computational approaches to identify disease-related miRNAs is beneficial in detecting the functions of miRNA biomarker for disease diagnosis, treatment, and prevention.

In this work, we develop a new method for measuring miRNA and disease similarities based on normalized mutual information. This method combines disease associated genes and disease DAG graphs to calculate disease similarity; and it calculates miRNA similarity based on miRNA-mRNA interactions. Given that no known association information is used in the similarity computation process, LOOCV does not overestimate the predicted performance. We then proposed NetCF for predicting new miRNA-disease associations by integrating miRNA and disease similarities with known miRNA-disease associations. Reliable AUC values for all comparable methods demonstrated that our proposed similarity computation method is reasonable and feasible. The AUC value of NetCF is superior to the other comparable methods, which indicates that NetCF has reliable predicted performance. Case studies further demonstrated the good predicted performance of NetCF for predicting potential and isolated disease-related miRNAs.

Even with the favorable results obtained using our method, this study reveals certain limitations. First, miRNA pair similarity is calculated based on the known common target genes because known miRNA-mRNA are scarce; thus, the similarities of many miRNA pairs are 0. The problem will be addressed considering that miRNA-target genes are increasingly recognized. In our future work, we will integrate more miRNA-related data to further improve the miRNA similarity measure. Second, future work should consider parameter optimization. For example, for the numbers of miRNA's neighbors and disease's neighbors, we separately choose 10% of the numbers of miR-NAs and diseases based on experiments. This selection works well in our dataset, but not necessarily for other datasets.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work is supported by the Program for National Nature Science Foundation of China (61672214, 61672223, 61572178, 61370171 and 61472127).

References

- 1 S. Chatterjee and H. Grosshans, Nature, 2009, 461, 546-549.
- 2 J. T. Mendell and E. N. Olson, Cell, 2012, 148, 1172-1187.
- 3 E. M. Small and E. N. Olson, Nature, 2011, 469, 336-342.
- 4 W. Shi, J. Du, Y. Qi, G. Liang, T. Wang, S. Li, S. Xie, B. Zeshan and Z. Xiao, *J. Psychiatr. Res.*, 2012, **46**, 198–204.
- 5 E. N. Olson, Sci. Transl. Med., 2014, 6(239), 239ps3.
- 6 Y. W. Kong, D. Ferland-McCollough, T. J. Jackson and M. Bushell, *Lancet Oncol.*, 2012, **13**, e249–258.
- 7 T. T. Manavalan, Y. Teng, S. N. Appana, S. Datta, T. S. Kalbfleisch, Y. Li and C. M. Klinge, *Cancer Lett.*, 2011, **313**, 26–43.
- 8 Y. Li, C. Qiu, J. Tu, B. Geng, J. Yang, T. Jiang and Q. Cui, *Nucleic Acids Res.*, 2014, **42**, D1070–D1074.

- 9 Q. Jiang, Y. Wang, Y. Hao, L. Juan, M. Teng, X. Zhang, M. Li,
 G. Wang and Y. Liu, *Nucleic Acids Res.*, 2009, 37, D98–D104.
- 10 Z. Yang, L. Wu, A. Wang, W. Tang, Y. Zhao, H. Zhao and A. E. Teschendorff, *Nucleic Acids Res.*, 2017, **45**, D812–D818.
- 11 Z. Yang, F. Ren, C. Liu, S. He, G. Sun, Q. Gao, L. Yao, Y. Zhang, R. Miao, Y. Cao, Y. Zhao, Y. Zhong and H. Zhao, *BMC Genomics*, 2010, **11**(4), S5.
- A. Ruepp, A. Kowarsch, D. Schmidl, F. Buggenthin, B. Brauner, I. Dunger, G. Fobo, G. Frishman, C. Montrone and F. J. Theis, *Genome Biol.*, 2010, 11, R6.
- 13 X. X. Zeng, X. Zhang and Q. Zou, *Briefings Bioinf.*, 2016, 17, 193–203.
- 14 D. Wang, J. Wang, M. Lu, F. Song and Q. Cui, *Bioinformatics*, 2010, **26**, 1644–1650.
- 15 J. Freudenberg and P. Propping, *Bioinformatics*, 2002, **18**(2), S110–S115.
- 16 M. A. van Driel, J. Bruggeman, G. Vriend, H. G. Brunner and J. A. Leunissen, *Eur. J. Hum. Genet.*, 2006, 14, 535–542.
- 17 Q. Zou, J. Li, L. Song, X. Zeng and G. Wang, *Briefings Funct.* Genomics, 2016, **15**, 55–64.
- 18 Q. Jiang, Y. Hao, G. Wang, et al., BMC Syst. Biol., 2010, 4(1), S2.
- 19 Q. Jiang, G. Wang and Y. Wang, An approach for prioritizing disease-related microRNAs based on genomic data integration, Biomedical Engineering and Informatics (BMEI), 2010 3rd International Conference On. IEEE, 2010, vol. 6, pp. 2270–2274.
- 20 Y. Liu, X. Zeng, Z. He and Q. Zou, *IEEE/ACM Trans. Comput. Biol. Bioinf.*, 2016, DOI: 10.1109/TCBB.2016.2550432.
- 21 X. Chen, M. X. Liu and G. Y. Yan, *Mol. BioSyst.*, 2012, **8**, 2792–2798.
- 22 H. Shi, J. Xu, G. Zhang, et al., BMC Syst. Biol., 2013, 7(1), 101.
- 23 H. Chen and Z. Zhang, BMC Med. Genomics, 2013, 6, 12.
- 24 P. Xuan, K. Han, M. Guo, et al., PloS one, 2013, 8(8), e70204.
- 25 X. M. Zhao, K. Q. Liu, G. H. Zhu, F. He, B. Duval, J. M. Richer, D. S. Huang, C. J. Jiang, J. K. Hao and L. N. Chen, *Bioinformatics*, 2015, **31**, 1226–1234.
- 26 G. M. Qin, R. Y. Li and X. M. Zhao, *IEEE/ACM Trans. Comput. Biol. Bioinf.*, 2016, 13, 1027–1035.
- 27 Q. Jiang, G. Wang, S. Jin, Y. Li and Y. Wang, International journal of data mining and bioinformatics, 2013, 8, 282–293.
- 28 X. X. Zeng, X. Zhang, Y. L. Liao and L. Q. Pan, *Biochim. Biophys. Acta, Gen. Subj.*, 2016, **1860**, 2735–2739.
- 29 C. Shi, X. N. Kong, Y. Huang, P. S. Yu and B. Wu, *IEEE Transactions on Knowledge and Data Engineering*, 2014, 26, 2479–2492.
- 30 X. Chen and G. Y. Yan, *Sci. Rep.*, 2014, 4, DOI: 10.1038/ srep05501.
- 31 J. Pinero, N. Queralt-Rosinach, A. Bravo, et al., Database, 2015, 2015, DOI: 10.1093/database/bav028.
- 32 S. D. Hsu, Y. T. Tseng, S. Shrestha, Y. L. Lin, A. Khaleel,
 C. H. Chou, C. F. Chu, H. Y. Huang, C. M. Lin, S. Y. Ho,
 T. Y. Jian, F. M. Lin, T. H. Chang, S. L. Weng, K. W. Liao,
 I. E. Liao, C. C. Liu and H. D. Huang, *Nucleic Acids Res.*,
 2014, 42, D78-D85.
- 33 S. D. Hsu, F. M. Lin, W. Y. Wu, C. Liang, W. C. Huang, W. L. Chan, W. T. Tsai, G. Z. Chen, C. J. Lee, C. M. Chiu,

C. H. Chien, M. C. Wu, C. Y. Huang, A. P. Tsou and H. D. Huang, *Nucleic Acids Res.*, 2011, **39**, D163–D169.

- 34 F. Ricci, L. Rokach and B. Shapira, *Introduction to recommender systems handbook*, Springer, 2011.
- 35 Y. Zhou, B. Song and H. T. Zheng, Exploiting Latent Relations Between Users and Items for Collaborative Filtering, *International Conference on Neural Information Processing*, Springer, Cham, 2015, pp. 365–374.
- 36 Q. Zou, J. Li, Q. Hong, et al., BioMed Res. Int., 2015, 2015, DOI: 10.1155/2015/810514.

- 37 S. McGuire, Adv. Nutr., 2016, 7, 418-419.
- 38 J. X. Cao, Y. Lu, J. J. Qi, G. S. An, Z. B. Mao, H. T. Jia, S. Y. Li and J. H. Ni, *Cell Death Discovery*, 2014, **5**, e1426.
- 39 S. T. Cha, P. S. Chen, G. Johansson, C. Y. Chu, M. Y. Wang, Y. M. Jeng, S. L. Yu, J. S. Chen, K. J. Chang, S. H. Jee, C. T. Tan, M. T. Lin and M. L. Kuo, *Cancer Res.*, 2010, 70, 2675–2685.
- 40 Y. Ouyang, P. Gao, B. Zhu, X. Chen, F. Lin, X. Wang, J. Wei and H. Zhang, *Mol. Med. Rep.*, 2015, **11**, 1435–1441.